Related Links

  • Merck
  • Elsevier Ltd is not responsible for the content of external websites.


Merck appoints Dr Michael Rosenblatt as Executive Vice President and Chief Medical Officer

Merck & Co. recently announced the appointment of Dr Michael Rosenblatt as Executive Vice President and Chief Medical Officer. Dr Rosenblatt will be Merck's primary voice to the global medical community.

Dr Rosenblatt will be responsible for bringing a greater focus to Merck’s medical activities worldwide and for shaping medical strategies. Dr Rosenblatt will report directly to Richard T. Clark (Merck’s chairman, president and CEO), will serve on the company’s Executive Committee and will lead the company's Global Center for Scientific Affairs.

‘Merck's fundamental mission is ensuring the well-being of patients worldwide and Dr Rosenblatt’s appointment reinforces our steadfast commitment to always remain focused on this goal,’ said Mr Clark. ‘Dr Rosenblatt's achievements in academia, clinical medicine and private industry are exceptional. With his nearly three decades of invaluable experience, I am pleased to welcome Dr Rosenblatt to Merck’s executive team.’

Dr Rosenblatt said, ‘Merck has built a great foundation on scientific innovation and dedication to the well-being of patients around the world and put an amazing team of researchers and scientists in place to drive the next wave of innovative products and services that save and improve lives. I look forward to working with my colleagues to make a difference in the lives of people around the world.’

Dr Rosenblatt has served as Dean of Tufts University School of Medicine since 2003. Before working at Tufts University, Dr Rosenblatt held the appointment of George R. Minot Professor of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center (BIDMC). He served as the President of BIDMC from 1999–2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at CareGroup and BIDMC and a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and BIDMC.

Before that, Dr Rosenblatt served as Director of the Harvard-MIT Division of Health Sciences and Technology. Earlier, he was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he co-led the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In leading most of Merck's international research efforts, he established two major basic research institutes. He also headed Merck Research's worldwide University and Industry Relations Department.

Dr Rosenblatt is the recipient of the Fuller Albright Award for his work on parathyroid hormone, the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck.

Share this article

More services


This article is featured in:
Companies and People


Comment on this article

You must be registered and logged in to leave a comment about this article.